Little NovaDigm races Pfizer, Glaxo in drive to develop MRSA vaccine

The lethal spread of MRSA in hospitals and other public places has been driving a number of programs aimed at finding a new vaccine capable of preventing tens of thousands of deaths each year. Bloomberg reports today that GlaxoSmithKline ($GSK), Pfizer ($PFE) and the small biotech NovaDigm Therapeutics all have promising but still early-stage vaccines in the pipeline. In NovaDigm's case, investigators have safety data from two Phase I studies, along with some proof-of-concept data on its ability to spur the development of white blood cells around vulnerable wounds. Pfizer and GSK are also pondering how to proceed as the demand for a new vaccine continues to grow. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.